TTX-MC138

Phase 2Small molecule

TTransCode Therapeutics

TTX-MC138 is one of 45 small molecule programs targeting HER2-positive Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HER2-Positive Breast CancerRecruiting

Advanced Solid TumorsActive, not recruiting

HER2-Positive Breast CancerPreclinical

Recruiting

Advanced Solid TumorsPhase 2

Active, not recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Trifluridine/tipiracil

AbbVie

Phase 2

2 2

BNT327

BioNTech

Phase 2

1 3

Standard Chemotherapy

Roche

Phase 2

1 4

Anti-PD-1 Monoclonal Antibody

IiTeos Therapeutics

Phase 2

3 5

GT201

GGrit Biotechnology

Phase 2

2 6

ZG006

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2

1 7

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Phase 2

1 8

Test Product HY07121

SSichuan Huiyu Pharmaceutical Co., Ltd

Phase 2

1 9

Dose Extension

IInstitute of Hematology & Blood Diseases Hospital, China

Phase 2

1 10

Simmitinib

SShanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Active, not recruiting

Advanced Solid Tumors

NCT06260774

Q4 2031

PreclinicalRecruiting

HER2-Positive Breast Cancer

NCT05868226

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Active, not recruiting·TTransCode Therapeutics·Phase 1/2·NCT06260774·16 enrolled

HER2-positive Breast Cancer1 trial

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

Recruiting·QQuantumLeap Healthcare Collaborative·Preclinical·NCT05868226·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TTX-MC138. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TTX-MC138 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TTX-MC138. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TransCode Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTransCode Therapeutics

TTX-MC138

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2031

Trials by Indication[1]

Advanced Solid Tumors1 trial

HER2-positive Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News